SCHEMBL2929429

SCHEMBL2929429

CC(=O)NCCn1cc2c(-c3ccc(F)cc3)c(-c3ccncc3)c(-c3ccc(F)cc3)nc2n1

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 17/20 0.45
MAPK11 Q15759 4/20 0.42
MAPK13 O15264 3/20 0.42
MAPK12 P53778 3/20 0.42
CSNK1D P48730 3/20 0.40
CSNK1E P49674 3/20 0.40
CSNK1A1 P48729 1/20 0.40
KCNH2 Q12809 2/20 0.38
NAMPT P43490 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2929740 0.94 MAPK14 (0.41) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2926478 0.90 MAPK14 (0.43) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2926579 0.90 ADORA3 (0.39) NAMPTALDH1A1
SCHEMBL2930642 0.90 MAPK14 (0.42) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2929818 0.89 MAPK14 (0.43) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2930511 0.89 MAPK14 (0.42) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2931853 0.89 RIPK3 (0.39) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2931774 0.87 MAPK14 (0.44) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL2926830 0.86 MAPK14 (0.45) MAPK14MAPK11MAPK13MAPK12CSNK1D
SCHEMBL1384858 0.86 MAPK14 (0.43) MAPK14MAPK11MAPK13MAPK12CSNK1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US claimed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP claimed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US claimed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US claimed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US claimed
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MAPK11 40/4885MAPK13 36/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885MAPK13 37/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MAPK11 40/4885MAPK13 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.